Cipla wants new-age medicines to contribute 10% of revenue in five years

Cipla is expanding its innovation ambitions while building manufacturing capacity in the US, as the drugmaker looks to diversify revenue streams and strengthen supply-chain resilience amid increasing regulatory and localisation pressures in global pharmaceutical markets.